This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While melanoma is a relatively rare form of skin cancer, the number of melanoma cases diagnosed has increased over the past several decades. Despite more overall cases, the melanoma mortality rate has decreased, in part due to earlier diagnosis. According to Dr. Yanes of U.S. Dermatology Partners Annapolis , “Early diagnosis is key to successfully treating melanoma.
Video Recap of AAAM (American Academy of Aesthetic Medicine) L+A attended AAAM Orlando on November 8th and 9th, where L+A Medical Editor, Dr. Chantal Lunderville was presenting. We had the opportunity to interview seven physicians who are part of the AAAM International Faculty. We’ve created a compilation of all of these interviews to share with the L+A Community.
Jerry Tan, MD, is joining Derm-Biome Pharmaceuticals, Inc.’s Scientific Advisory Board. Dr. Jerry Tan, is a dermatologist in Windsor, ON, the immediate past President of the Acne and Rosacea Society of Canada, co-chair of the Acne Core Outcomes Research Network (ACORN), Derm-Biome Pharmaceuticals develops topical treatments for acne, atopic dermatitis, and precancerous skin conditions.
Panelists discuss how setting long-term treatment goals for basal cell carcinoma (BCC) patients involves balancing factors such as disease control, quality of life, and potential adverse reactions to create personalized management plans that address both immediate concerns and future outcomes.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content